Loading…
Reported covered position: House Committee on Energy & Commerce, Clerk
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare Patient Access to Hospice Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2013 · first_quarter · Q1
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Source: Senate LDA
Saint Francis Dam Disaster National Memorial Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To amend the National Environmental Policy Act of 1969 to clarify that no Federal agency shall be required to consider the social cost of carbon as a condition of compliance with such Act, and for other purposes.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Air and Health Quality Empowerment Zone Designation Act of 2013
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
CHIP Extension and Improvement Act of 2014
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to implementation of the Prescription Drug User Fee Act (now Public Law 112-144)
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (S.3187)
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) ); Drug Shortages Prevention Act of 2012 (H.R. 3839))
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) ); Drug Shortages Prevention Act of 2012 (H.R. 3839))
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Drug Shortage Prevention Act of 2012
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) ); Drug Shortages Prevention Act of 2012 (H.R. 3839))
To suspend temporarily the duty on 3-[8-Amino-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin- 3-yl]-1-methyl-cyclobutanol (OSI-906).
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on 3-[8-Amino-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin- 3-yl]-1-methyl-cyclobutanol (OSI-906).
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on 3-[8-Amino-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin- 3-yl]-1-methyl-cyclobutanol (OSI-906).
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASP2408.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASP2408.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASP2408.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASP0777.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASP0777.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASP0777.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on 3-(1-Bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone (OSIP-690631, bicyclic intermediate).
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on 3-(1-Bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone (OSIP-690631, bicyclic intermediate).
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on 3-(1-Bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone (OSIP-690631, bicyclic intermediate).
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASKP1240.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASKP1240.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASKP1240.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182/S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) )
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182/S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) )
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2012 · fourth_quarter · Q4
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2012 · third_quarter · Q3
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to implementation of the Prescription Drug User Fee Act (now Public Law 112-144)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2012 · second_quarter · Q2
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (S.3187)
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2012 · first_quarter · Q1
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) ); Drug Shortages Prevention Act of 2012 (H.R. 3839))
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182/S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) )
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE